SIRION Biotech Names LaVoieHealthScience as Strategic Communications Agency of Record

SIRION Biotech Plans Path for US Market Expansion

Boston, MA & Martinsried, Germany – November 4, 2018 – LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced that Europe’s leading gene therapy engineer of viral vectors, SIRION Biotech GmbH, is now a client of LaVoieHealthScience.  LHS provides strategic communications programming and corporate development expertise to SIRION Biotech, helping to connect SIRION Biotech to relevant stakeholders in the U.S. life science ecosystem.  This is particularly important as SIRION Biotech plans its expansion into the U.S. market with its new Cambridge, MA site beginning January 2019.

SIRION Biotech has been engaged in research and licensing collaborations with 3 leading US biotechs in the gene therapy field since 2015. The earliest project was assisted by LaVoieHealthScience beginning in 2014, when the Germany based company with deep scientific roots in gene expression was seeking U.S. partnerships with clinical-stage gene therapy companies in order to expedite their R&D efforts.  Partnering together, LaVoieHealthScience and SIRION Biotech built its US profile, visibility and outreach efforts. 

“Partnering with LaVoieHealthScience helped us unleash our potential as a business to business provider of custom engineered viral vectors for industrial and academic research and development,” said Chief Operating Officer and Executive Director, Dieter Lingelbach.  Our planned expansion into the US market will be a strategic imperative for SIRION Biotech and we are delighted to continue working with LaVoieHealthScience as we chart our course forward.”

“We are fortunate to continue working with SIRION Biotech as Europe’s leader in the field on its next stage of growth and continue our successful partnership together, said Donna L. LaVoie, President & CEO of LaVoieHealthScience.  Dieter and founder, Chief Technology Officer, Dr. Christian Thirion have great vision to enable gene therapy and gene editing companies become more successful with the right clinical grade vector technology that will scale through manufacturing.”

About LaVoieHealthScience

LaVoieHealthScience provides public relations, investor relations, marketing and digital communications to build recognition and value for health science innovators. The agency has received more than 30 awards during the past seven years in recognition of the work it has done for its industry-leading clients and was recently inducted into the 2018 Inc. 5000 Hall of Fame list of Fastest Growing Private Companies. LaVoieHealthScience represents public and privately-held leaders such as BIO, Carmell Therapeutics, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, SIRION Biotech, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies. For more information, please visit: https://lavoiehealthscience.com/

 

About SIRION Biotech GmbH

SIRION Biotech provides custom engineering and manufacturing services of viral vectors for the life sciences and industry. Its unique focus on improving transduction efficiencies and safety make SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOSTTM transduction reagent is actively used to improve hematopoitec cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies.

www.sirion-biotech.com

 

###

Media Contact:
Katie Gallagher
Account Manager, PR and Marketing

kgallagher@lavoiehealthscience.com
617-374-8800 x109

 

Emmaus Life Sciences Names LaVoieHealthScience as Strategic Communications Agency of Record

Boston, MA & Torrance, California –

November 7, 2018 – LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced that it has added Emmaus Life Sciences, Inc. (Emmaus) to its client roster. LHS provides strategic communications programming to Emmaus, helping to ensure all stakeholders – including patients, healthcare practitioners, investors, and other audiences – are educated and aware of sickle cell disease and Emmaus’ dedication to patients with this orphan disease.

Emmaus has a history rooted in scientific discovery. Endari™ (L-glutamine oral powder), approved in July 2017, was developed by Emmaus’ Chairman and CEO Yutaka Niihara, M.D., MPH. Dr. Niihara began researching the benefits of L-glutamine more than 25 years ago in 1992, as a physician treating sickle cell patients at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Today, the company’s product pipeline includes the potential use of L-glutamine to treat diverticulosis, a GI condition affecting millions, as well as diabetes. In addition, Emmaus is researching cell-sheet technology for treatment of limbal stem-cell deficiency, an orphan disease.

“We understand the importance of extending our visibility and building patient awareness of the treatment options for this debilitating orphan disease,” commented Kurt Kruger, CFO of Emmaus Life Sciences. “LHS, with its focus and expertise in the health and life science industry and connections with influencers, investment community and media make it the right partner for Emmaus.”

“We are honored to be working with Emmaus, a company led by Dr. Niihara that is truly passionate about patients and committed to medical innovation,” said Donna L. LaVoie, President & CEO of LaVoieHealthScience. “We are aligned with Emmaus’ passion to help patients afflicted with sickle cell disease and to raise the visibility of this disease, and the company’s important contributions to this underserved patient community.”

About Endari™ (L-glutamine oral powder)

Indication
Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.

Important Safety Information
The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.

Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.

The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.

For more information, please see full Prescribing Information of Endari at: www.ENDARIrx.com/PI.

About LaVoieHealthScience

LaVoieHealthScience provides public relations, investor relations, marketing, and digital communications to build recognition and value for health science innovators. The agency has received more than 30 awards during the past seven years in recognition of the work it has done for its industry-leading clients and was recently inducted into the 2018 Inc. 5000 Hall of Fame list of Fastest Growing Private Companies. LaVoieHealthScience represents public and privately-held leaders such as BIO, Carmell Therapeutics, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, SIRION Biotech, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies. For more information, please visit: https://lavoiehealthscience.com/

###

Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
kgallagher@lavoiehealthscience.com    
617-374-8800 x109

 

LHS Partners with LSX World Congress USA

 
 
The LSX World Congress brought life science executives together here in Boston for strategy, investment, and partnering opportunities. As an event partner, LHS is thrilled to have participated in several key event tracks, including IPO Bootcamp, the Big Data Driven Innovation panel and two Fireside Chats.  
Fireside chat with Donna LaVoie and Pavan Cheruvu

As co-host of the IPO Bootcamp, held on Tuesday, October 9, at the Union Club in Boston, LHS was thrilled to be the investor relations consultant for executives looking for best practices for a successful IPO. The day began with an opening address from David Ethridge of PwC on the current state of the IPO market, and continued with an overview of the healthcare ECM from Jordan Saxe, Senior Managing Director at Nasdaq. A roundtable discussion on determining and defining an IPO strategy followed, with leaders from PwC, Nasdaq, Covington & Burling, Oppenheimer & Co, and LavoieHealthScience offering insights.

We are also grateful to have had SVP and General Manager, Doug Russell, moderate the LSX panel on Big Data Driven Innovation on Thursday, October 11.  Pharma and life science executives discussed how they’re harnessing the power of big data to advance drug discovery and development. Panelists included Leila Pirhaji, Founder and CEO of ReviveMed, Josh Mandel-Brehm, CEO of Camp4 Therapeutics, Gini Desphande, Founder and CEO of NuMedii, Alex de Winter, Managing Director at GE Ventures, and Janna Hutz, Senior Director, Head of Human Biology & Data Science at Eisai.  Doug led a lively discussion on the topic, with a focus on the future promise of big data in life science innovation.

Big Data Panel with Doug Russell
Fireside Chat with Paul Sagan and Brian Pereira

CEO Donna LaVoie and Paul Sagan, AVP, Investor Relations and Communications, also conducted fireside chats with pharma executives at the LSX World Congress.  Pavan Cheruvu, the CEO of Axovant, spoke with Donna LaVoie on the details of building a successful gene therapy portfolio.  Later in the evening, Paul Sagan and Brian Pereira, the CEO of Visterra, discussed the anatomy of a clinical-stage acquisition.  Pereira, whose company was recently acquired by the Pharmaceutical Co., Ltd of Japan, offered a timely and relevant perspective on the topic. 

The two day conference offered many interesting and engaging panels as well as great networking opportunities. LHS is happy to have partnered with LSX this year for a successful World Congress.

LaVoieHealthScience to Co-Host the IPO Bootcamp at the LSX World Congress USA

Our agency is excited to be co-hosting the IPO Bootcamp at the LSX World Congress on October 9, 2018 in Boston, MA.

The IPO Bootcamp is a full day immersive workshop focused on effectively navigating the nuances of an initial public offering.  In addition to LHS, this bootcamp is co-hosted with Covington & Burling LLP, Nasdaq, and Oppenheimer & Co, Inc.  LHS will provide personalized expertise on public relations, investor relations, and corporate communications strategy to nine attending CEOs.

Executives planning to take their company public have the opportunity for 1:1 sessions with co-hosts to explore individualized mechanics, ideas, and best practices throughout the IPO process.  Discussions will be thorough and transparent, offering companies quality insights on the ins and outs of a successful IPO.

Discussions include:

  • Keynote address: the current state of capital markets
  • Anatomy of an IPO: Back to back case study discussions of IPOs
  • Legal preparations
  • Financial PR and communications
  • Regulatory requirements and IPO checklists

The IPO Bootcamp will take place one day prior to the LSX World Congress USA conference, which offers education, strategies, and solutions for life science executives to grow their business. The event will be held at the Union Club at 8 Park St, Boston, MA.

LaVoieHealthScience Promotes Sharon Correia to Senior Vice President, Integrated Communications

Boston, MA – September 5, 2018 – LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced the promotion of Sharon Correia to Senior Vice President, Integrated Communications.

Ms. Correia joined LHS in 2016 as Vice President, Integrated Communications from Navidea Biopharmaceuticals, where she was Sr. Director of Corporate Communications. An industry veteran with more than two decades of health and science communications experience spanning agency, publicly-traded and private companies, Sharon designs and executes programs that resonate from development phase through commercialization. Sharon has demonstrated alignment with LHS’s core values and a fast-moving, collaborative culture focused on problem solving.

“I am delighted to celebrate Sharon’s success at LHS and the engagement and experience that she brings to our people, clients and community. In her new role, Sharon continues to report to me and works with the senior leadership team on client strategy, execution, team building and high-level programming,” stated Donna L. LaVoie, President & CEO of LaVoieHealthScience.

Sharon brings industry-tested integrated communications experience spanning public and medical communications, investor communications and professional advocacy relations. She’s led communications teams for multiple new drug applications in the US and EU, global product launches as well as several sNDA’s, IPOs and key data dissemination at medical meetings.

“I am truly excited to continue to contribute my expertise to the well-regarded group of specialized thinkers at LHS who are solving client problems and helping them advance health and science innovation,” said Correia. “Each and every LHS client provides our team with unique and dramatic perspectives on how creative story-telling creates competitive advantage.”

About LaVoieHealthScience
LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies. LaVoieHealthScience represents leaders such as, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies.

###

Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
kgallagher@lavoiehealthscience.com
617-374-8800 x109

LaVoieHealthScience Enters Inc. 5000 Hall of Fame as Five-Year Honoree

Demand for Integrated Investor and Public Relations Services from Health Science Innovators Drives 73% Three-Year Growth   

 

LaVoieHealthScience has been recognized on the prestigious Inc. 5000 list for the fifth time. This puts LaVoieHealthScience in the Inc. 5000 Hall of Fame – an honor bestowed on only 10% of listed companies.  Each year, Inc. magazine recognizes the fastest-growing private companies in the U.S., showcasing the immense level of development throughout the country. The list was released on August 15, 2018 and can be viewed here: https://www.inc.com/inc5000/index.html

“We are extremely proud to have achieved a spot on the Inc. 5000 for a third year in a row and fifth year overall – and entering the Hall of Fame is icing on the cake,” said Donna LaVoie, President and CEO of LaVoieHealthScience. “Our three-year growth rate of 73% is testament to our domain expertise and track record of providing strategic, integrated communications services to health and science clients worldwide. We’ve assembled a terrific roster of clients and a seasoned team of strategic advisors – positioning us well for further growth and momentum!”

About LaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies. LaVoieHealthScience represents leaders such as, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies.

LaVoieHealthScience Selected as a PRNews Platinum Award Finalist

Award Recognizes Excellence in Financial/Investor Relations

 

Boston, MA- August 22, 2018- LaVoieHealthScience (LHS),  an integrated investor and public relations agency focused on advancing health and science innovations, has been selected as a PRNews Platinum Award finalist in the Investor/Financial Relations Campaign category. The awards ceremony will take place on September 21st, 2018 at the Grand Hyatt in NYC. The nomination is for the agency’s work on behalf of its client Ampio Pharmaceuticals, a development stage biopharmaceutical company focused on novel therapies to treat common inflammatory conditions.

LaVoieHealthScience developed a multi-faceted financial/investor relations integrated communications plan for Ampio to optimize the impact of the release of pivotal Phase 3 data results for their leading drug candidate Ampion™, a treatment for severe osteoarthritis of the knee.

The campaign included traditional, paid and social media, and was designed to reach all stakeholders with concise and compelling messaging for a broad audience. This included patients, physicians, strategic partners and investors. The campaign also included a press release that was offered to reporters under embargo, as well as a post-distribution follow-on campaign that targeted the full range of national, local, business, trade and orthopedic outlets. The campaign included sponsored print and radio content.

“LaVoieHealthScience is thrilled to be selected as a finalist for the PRNews Platinum Awards for our client Ampio Pharmaceuticals,” said Donna L. LaVoie, President & CEO, LaVoieHealthScience. “This is a stand-out example of how to gain maximum visibility through an integrated campaign using paid, earned and social media.”

The PRNew’s Award follows LaVoieHealthScience taking home the Silver Bell Ringer Award in the Investor/Financial Relations Campaign category from the Publicity Club of New England at the 50th Annual Bell Ringer Awards in Boston. This honor was also for their work with Ampio Pharmaceuticals in the same category as their newest nomination.

About LaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies. LaVoieHealthScience represents leaders such as, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies.

 

Contact:
LaVoieHealthScience
Katie Gallagher
Investor Relations & Corporate Communications
kgallagher@lavoiehealthscience.com

LaVoieHealthScience Adds XenoTherapeutics to Client Roster

Boston-based XenoTherapeutics Aims to Bring Life-Saving Innovation from The Lab to Address the Global Shortage of Transplantable Organs and Tissues

Boston, MA – July 20, 2018 –  LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced the addition of XenoTherapeutics to its client roster as its agency of record for strategic communications. XenoTherapeutics is partnering with LHS to build a messaging framework to educate stakeholders on the company’s proprietary platform technology to advance xenotransplantation, the science of transplanting organs and tissues of different species.

XenoTherapeutics’ mission is to provide innovative, affordable, and safe medical solutions to patients in critical need in both the U.S. and around the globe.  Its initial product candidate, Xeno-Skin, is intended to serve as a replacement or a complement to the current “gold standard” of burn treatment: human cadaver allograft. However, unlike the limited quantity of lifesaving human graft material available, Xeno-Skin is intended to be mass-produced, stored, and rapidly shipped when needed. Ultimately, the goal is to increase emergency preparedness for unexpected catastrophic events at home and fill current shortages experienced far too frequently around the world today. The XenoTherapeutics pipeline starts with skin, but envisions myriad applications of the technology, including nerves and solid organs.

“In selecting a communications partner, we did our due diligence,” said Paul Holzer, Co-founder and Chief Executive Officer of XenoTherapeutics. “LHS stood out with its deep understanding of the business and regulatory aspects of science and medicine, its team of high-touch senior leaders, and proprietary approach to creating targeted messaging mapped to stakeholders as the underpinning of a strategic communications program. We are looking forward to a long and fruitful relationship.”

Donna L. LaVoie, President & CEO of LaVoieHealthScience commented, “We are delighted to be working with the XenoTherapeutics team to bring attention to their pioneering work in seeking to address the worldwide shortage of organs for transplantation. Headed by a former U.S. Navy SEAL, XenoTherapeutics’ entrepreneurial culture, sense of purpose, and innovative technology based on rigorous scientific research has the potential to be an industry game-changer.”

About XenoTherapeutics

XenoTherapeutics’ goal is to provide safe, scalable transplantation solutions based on three decades of research by some of the world’s top leaders in xenotransplantation, surgery and infectious disease. The company’s proprietary platform leverages genetically-engineered pigs to provide a supply of temporary tissues and organs that are less susceptible to human rejection.

The company has developed a non-human organ transplant solution currently under investigational review by the FDA, which has the potential to catalyze the science of xenotransplantation and address a critically unmet need for organs and tissues across the globe. For more information, please visit: https://www.xenotherapeutics.org/

LaVoieHealthScience Honored with Silver Bell Ringer Award for Investor/Financial Relations Campaign

Campaign Optimized On-Message Coverage of Pivotal Phase 3 Data

BOSTON, MA – June 14, 2018 – LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, announced today it has won a Silver Bell Ringer Award in the Investor/Financial Relations Campaign category from the Publicity Club of New England for the agency’s work on behalf of its client, Ampio Pharmaceuticals (NYSE MKT: AMPE), a development stage biopharmaceutical company focused on the discovery and development of novel therapies aimed at treating common inflammatory conditions for which there are limited treatment options.

LaVoieHealthScience developed an Investor/Financial Relations strategic communications campaign to ensure on-message visibility for Ampio’s announcement of pivotal data for Ampion™ for the treatment of osteoarthritis of the knee.

The campaign included a press release that was offered to reporters on an embargoed basis, as well as a post-distribution follow-on campaign that targeted the full range of national, local, business, trade and orthopedic outlets. In addition to the earned media, the campaign included sponsored print and radio content. An important part of the campaign also included a full suite of “infrastructure” including detailed timelines and Q&A preparation.

“I want to thank our talented team and our client, Ampio for their specialized thinking and spot-on execution on this important investor communications program.  We are honored to be recognized again in 2018 by the Publicity Club of New England,” stated Donna L. LaVoie, President and CEO.

Since 1969, the Publicity Club of New England’s Bell Ringer Awards have been a symbol of outstanding achievement for New England public relations and communications professionals in every field and industry and across all forms of media.

About LaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides strategic communications, investor relations and public relations to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients and is ranked among the 2017 Inc. 5000 list of fastest growing private companies for the fourth year. In addition to clients listed above, LaVoieHealthScience represents leaders such as Affimed, BioAxone BioSciences, Biotechnology Innovation Organization, Fusion Pharmaceuticals, Genosco, Landos Biopharma, LEO Science Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Biosystems, Scioto Biosciences, Symbiotix, Triumvira Immunologics, Xontogeny LLC, XenoTherapeutics and other emerging health and science companies.

###

Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
kgallagher@lavoiehealthscience.com
617-374-8800 x109

LaVoieHealthScience to Co-Host the Writing for PR and Corporate Communications Conference

LaVoieHealthScience an integrated investor and public relations agency focused on advancing health and science innovations, today announced the agency will co-host The Writing for PR and Corporate Communications Conference with McDermott, Will & Emery taking place on August 1 – 2, 2018 in Boston, MA. Register for this event today!

This conference will help guide your writing, harness your corporate story, strike a chord with your stakeholders and increase your media pitch success rate. Over the two days you will attend sessions hosted by members of The New York Times, Cape Cod Healthcare and Dell Technologies to name a few. These sessions are intended to help those whose responsibilities include: writing and editing, corporate communications, public relations, internal communications, corporate storytelling, intranets, marketing and content creation.

Sample sessions include:

  • Creating (and delivering) an integrated message through executive communications
  • Secrets of success: Apply real-world tools to drive clicks, traffic and ROI
  • Audience first: Answering ‘What’s in it for me?’ in internal and external messaging
  • Pitch tank: Pitch our panel of journalists and see if your story sinks or swims

This conference offers exhibitor booths, speaking sessions, pre-conference workshop sessions, networking lunches, one-on-one meetings, marketing collateral and on-site branding and much more. It will be held at McDermott Will & Emery LLP at 28 State Street, Boston, MA.